Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma

Early Phase 1

Active, not recruiting

• Conditions: Pancreas Cancer; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Metastatic Cancer
• Interventions: Drug: Cholesterol metabolism disruption

• Registration Number: NCT04862260
• Lead Sponsor: CHU de Quebec-Universite Laval

Brief Summary

Cardiovascular diseases and cancers, the two leading causes of death in Canada, require cholesterol to sustain their progression. All cells require cholesterol, but cancer cells have much higher needs to sustain growth, division and metastasis. The availability of new cholesterol-lowering drugs developed to protect patients from heart diseases has resulted in unprecedented low levels of cholesterol. The combination of atorvastatin, ezetimibe and Repatha, which are 3 cholesterol-lowering drugs used in combination, is safe, well tolerated and efficient over years of treatment. Recent reports indicate that abundant cholesterol supplies are required to sustain the progression of pancreatic ductal adenocarcinomas. This proof-of-concept study aims to verify the feasibility, the acceptability and gain preliminary data on adding a cholesterol shortage on top of FOLFIRINOX (standard chemotherapy) in newly diagnosed patients with locally advanced pancreatic adenocarcinomas or metastatic pancreatic adenocarcinomas. It is expected that a drug-induced cholesterol shortage will slow-down or stop the progression of pancreatic adenocarcinomas while increasing the response to chemotherapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-04-06
• Study First Submitted QC: 2021-04-23
• Study First Posted: 2021-04-27
• Study Start: 2021-10-04
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-21
• Last Update Posted: 2024-05-22
• Primary Completion: 2025-01-31
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

To be eligible to this trial, patients must fulfill the following inclusion criteria:

1. Have a histologically confirmed, treatment-naive locally advanced and inoperable (LaiPDAC) or metastatic pancreatic ductal adenocarcinoma (mPDAC).

2. Be at least 18 years or older at the time of signing the informed consent.

3. Have a life expectancy of at least 12 weeks.

4. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale.

5. Have measurable disease as assessed by RECIST v1.1.

6. Agrees and amenable to a tumor (if deemed safe only) and liver biopsy (all participants) at baseline and on day 42 +/- 3 days. Patient that are anticoagulated at baseline are eligible provided it is deemed safe by the investigator to stop anticoagulation momentarily in order to safely proceed to a biopsy.

7. Eligible to standard-dose FOLFIRINOX as assessed by the principal investigator or a sub-investigator. FOLFIRINOX doses can be adapted according to SOC.

8. Demonstrate normal organ function as defined below. These assessments must be done within 7 days of Cycle 1 Day-7.

   Hemoglobin (Hb) ≥ 90 g/L Absolute neutrophil count ≥ 1.5 x 10 9/L Platelet count ≥ 100 x 10 9/L INR ≤ 1.3 (unless patient is anticoagulated*) aPTT ≤ 1.5 x ULN (switching to LMWH will be recommended) Total bilirubin ≤ 1.5 x ULN OR Direct bilirubin (for patients with total bilirubin ≥ 1.5 x ULN) AST and ALT ≤ 3 x ULN CPK ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x ULN OR Estimated GFR (as per institutional standards) ≥ 50 ml/min

9. Provide written informed consent and able to follow the trial treatment and visit schedule.

10. For Women Of Child-Bearing Potential (WOCBP), a negative serum pregnancy test must be obtained prior to receiving the study medication.

11. WOCBP should agree to use 2 different methods of birth control OR abstain from heterosexual intercourse for the duration of the trial and up to 90 days after the last study medication administration.

12. Male subjects should agree to use an adequate method of contraception for the duration of the trial and up to 90 days after the last study medication administration. Male subjects should refrain from donating sperm during this period.

Exclusion Criteria

To be eligible to this trial, patients must not fulfill any of the following exclusion criteria:

1. Locally advanced pancreatic ductal adenocarcinoma deemed operable.
2. Any pancreatic ductal adenocarcinoma deemed operable or borderline operable that can be treated with neoadjuvant chemotherapy.
3. Known additional malignancy that is progressing or that requires treatment. Exceptions include basal cell carcinoma of the skin, in situ bladder or in situ cervical cancer. Other malignancy may be eligible after consultation with the promotor-investigator.
4. Spinal cord compression or brain metastases unless treated, stable and not requiring steroids for at least 4 weeks prior to the initiation of study treatment.
5. Baseline myalgia or myositis of any etiology.
6. Prior treatment with FOLFIRINOX in the adjuvant setting.
7. History of clinically significant intolerance or myositis with any statin.
8. History of clinically significant intolerance or hypersensitivity to PCSK9 inhibitors or ezetimibe.
9. Baseline grade ≥ 2 ULN Creatine Phosphokinase (CPK) elevation.
10. Liver tumor burden that is deemed unsafe by the investigator.
11. Major surgery or procedure from which the patient has not yet recovered.
12. Any medical condition that puts the patient at high medical risk, including but not limited to active uncontrolled infection or active bleeding diathesis.
13. Any history of disease that, in the opinion of the investigator, puts liver function at risk including but not limited to autoimmune hepatitis or history of hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Screening at baseline for those conditions is not required.
14. Use of any drugs that are contraindicated as per protocol and that cannot be changed or modified to an acceptable alternative.
15. Active smoker. Complete usage of tobacco must have been stopped for at least 3 months.
16. Abnormally low hematocrit, as assessed by the oncologist.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Multipathway cholesterol metabolism disruption	Cholesterol metabolism disruption	Twelve to fifteen patients will receive a combination of daily atorvastatin 40 mg, twice daily ezetimibe 10 mg and evolocumab 420 mg subcutaneously every month. This multipathway cholesterol metabolism disruption will be combined to standard chemotherapy (FOLFIRINOX).

Primary Outcome Measures

Name	Time	Method
Characterization of dose-limiting toxicities	2 years	To determine the dose at which no more than 1 out of 6 patients experience a drug related dose-limiting toxicity. To confirm that the combination of daily atorvastatin 40 mg, ezetimibe 10 mg twice daily and monthly evolocumab 420 mg meets the criterion to be the recommended phase II dose (RP2D).
Safety as measured by the rate of adverse events	2 years	To determine causality and grading severity of each adverse event (AEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Secondary Outcome Measures

Name	Time	Method
LDLR (low-density lipoprotein receptor) tumoral and hepatic changes in response to the multipathway cholesterol embargo.	1 year	Assessment of the level of LDLR in the tumor (hepatic metastasis ) and the liver by immunohistochemistry.
NPC1L1 (Niemann-Pick C1-Like 1 protein) tumoral and hepatic changes in response to the multipathway cholesterol embargo.	1 year	Assessment of the level of NPC1L1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry.
SRB1 (Scavenger Receptor class B type 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo.	1 year	Assessment of the level of SRB1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry.
MHC-1 (Major Histocompatibility Complex class 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo.	1 year	Assessment of the level of MHC-1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry
Change in tumoral and hepatic levels of TILs (Tumor-Infiltrating Lymphocytes)	1 year	Assessment of tumoral and hepatic levels of TILs by immunohistochemistry
CD36 (Cluster of Differentiation 36) changes in response to the multipathway cholesterol embargo	1 year	Assessment of tumoral and hepatic levels in the tumor (hepatic metastasis ) and the liver by immunohistochemistry.
LRP1 (Low-density lipoprotein Receptor-Related Protein 1) tumoral and hepatic changes in response to the multipathway cholesterol embargo.	1 year	Assessment of the level of LRP1 in the tumor (hepatic metastasis ) and the liver by immunohistochemistry.
PD-L1 (Programmed Death-Ligand-1) changes in response to the multipathway cholesterol embargo.	1 year	Assessment of the level of PD-L1 (Programmed Death-Ligand-1) in the tumor (hepatic metastasis ) and the liver by immunohistochemistry.

Trial Locations

Locations (2)

CHUM; 🇨🇦 Montreal, Quebec, Canada

CHU de Québec-Université Laval; 🇨🇦 Quebec city, Quebec, Canada